Circulation, 146, 657-672 Circulation : an official journal of the American Heart Association / ed.-in-chief Ephraim Donosco 146(9), 657-672 (2022). doi:10.1161/CIRCULATIONAHA.121.057807 Hagström, E, Steg, P G, Szarek, M, Bhatt, D L, Bittner, V A, Danchin, N, Diaz, R, Goodman, S G, Harrington, R A, Jukema, J W, Liberopoulos, E, Marx, N, McGinniss, J, Manvelian, G, Pordy, R, Scemama, M, White, H D, Zeiher, A M, Schwartz, G G, ODYSSEY OUTCOMES Investigators & Bøttcher, M 2022, ' Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab ', Circulation, vol. 146, no. 9, pp. 657-672 . https://doi.org/10.1161/CIRCULATIONAHA.121.057807 Circulation, vol 146, iss 9 Circulation, 146, 9, pp. 657-672 Circulation, Philadelphia : Lippincott Williams & Wilkins, 2022, vol. 146, iss. 9, p. 657-672 Circulation, 146(9), 657-672. LIPPINCOTT WILLIAMS & WILKINS
Journal of the American College of Cardiology, 78(5), 421-433. ELSEVIER SCIENCE INC Journal of The American College of Cardiology, New York : Elsevier Biomedical, 2021, vol. 78, no. 5, p. 421-433 Repositorio Universidad de Santander Universidad de Santander instacron:Universidad de Santander Schwartz, G G, Szarek, M, Bittner, V A, Diaz, R, Goodman, S G, Jukema, J W, Landmesser, U, López-Jaramillo, P, Manvelian, G, Pordy, R, Scemama, M, Sinnaeve, P, White, H D, Gabriel Steg, P, Gabriel Steg, P H, Bhatt, D L, Harrington, R A, Zeiher, A M, Tricoci, P, Roe, M T, Mahaffey, K W, Edelberg, J M, Hanotin, C, Lecorps, G, Moryusef, A, Sasiela, W J, Tamby, J F, Aylward, P E, Drexel, H, Sinnaeve, P, Dilic, M, Lopes, R D, Gotcheva, N N, Prieto, J C, Yong, H, Pećin, I, Reiner, Z, Clemmensen, P, Bang, L E, Hove, J D, Gislason, G, Larsen, J, Johansen, P, Jeppesen, J, Nielsen, P K, Hansen, O, Jensen, S A, Rosenberg, M, Andersen, D & ODYSSEY OUTCOMES Committees and Investigators 2021, ' Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol ', Journal of the American College of Cardiology, vol. 78, no. 5, pp. 421-433 . https://doi.org/10.1016/j.jacc.2021.04.102 Schwartz, G G, Szarek, M, Bittner, V A, Diaz, R, Goodman, S G, Jukema, J W, Landmesser, U, López-Jaramillo, P, Manvelian, G, Pordy, R, Scemama, M, Sinnaeve, P, White, H D, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2021, ' Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol ', Journal of the American College of Cardiology, vol. 78, no. 5, pp. 421-433 . https://doi.org/10.1016/j.jacc.2021.04.102 Journal of the American College of Cardiology, vol 78, iss 5
Lancet Diabetes & Endocrinology r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname The Lancet Diabetes & Endocrinology Volume 7 Issue 8 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tuñón, J, White, H D, Zeiher, A M, Schwartz, G G, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tuñón, J, White, H D, Zeiher, A M, Schwartz, G G, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Lancet diabetes & endocrinology ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tunon, J, White, H D, Zeiher, A M, Schwartz, G S, Steg, P G, Schwartz, G G, Steg, P G, ODYSSEY OUTCOMES Committees and Investigators, Clemmensen, P, Gislason, G, Nielsen, P K, Davidsen, F, Andersen, D, Jeppesen, J & Videbæk, L 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA Lancet Diabetes and Endocrinology, 7(8), 618-628. ELSEVIER SCIENCE INC
The Lancet The Lancet, Elsevier, 2019, 394 (10204), pp.1169-1180. ⟨10.1016/S0140-6736(19)31887-2⟩ The Lancet (London), 394, 1169-1180 Bhatt, D L, Steg, P G, Mehta, S R, Leiter, L A, Simon, T, Fox, K, Held, C, Andersson, M, Himmelmann, A, Ridderstråle, W, Chen, J, Song, Y, Diaz, R, Goto, S, James, S K, Ray, K K, Parkhomenko, A N, Kosiborod, M N, McGuire, D K, Harrington, R A & THEMIS Steering Committee and Investigators 2019, ' Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial ', Lancet, vol. 394, no. 10204, pp. 1169-1180 . https://doi.org/10.1016/S0140-6736(19)31887-2 The Lancet (London), 394, 10204, pp. 1169-1180